

4-(6-*tert*-Butyl-8-fluoro-1-oxo-1*H*-phthalazin-2-yl)-3-hydroxymethyl-5'-(5-methanesulfonyl-pyridin-2-ylamino)-1'-methyl-1'*H*-[2,3']bipyridinyl-6'-one;

6-*tert*-Butyl-2-[4-(5-{5-[2-(3,3-difluoro-azetidin-1-yl)-1,1-dimethyl-ethoxy]-pyridin-2-ylamino}-1-methyl-6-oxo-1,6-dihydro-pyridazin-3-yl)-3-hydroxymethyl-pyridin-2-yl]-8-fluoro-2*H*-phthalazin-1-one;

2-(8-Fluoro-2-{3-hydroxymethyl-4-[1-methyl-5-(5-methyl-4,5,6,7-tetrahydro-pyrazolo[1,5-*a*]pyrazin-2-ylamino)-6-oxo-1,6-dihydro-pyridazin-3-yl]-pyridin-2-yl}-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-methyl-propionitrile;

2-{2-[4-(5-{5-[2-(3,3-Difluoro-azetidin-1-yl)-1,1-dimethyl-ethoxy]-pyridin-2-ylamino}-1-methyl-6-oxo-1,6-dihydro-pyridazin-3-yl)-3-hydroxymethyl-pyridin-2-yl]-8-fluoro-1-oxo-1,2-dihydro-isoquinolin-6-yl}-2-methyl-propionitrile;

6-*tert*-Butyl-2-[4-(5-{5-[2-(3,3-difluoro-azetidin-1-yl)-1,1-dimethyl-ethoxy]-pyridin-2-ylamino}-1-methyl-6-oxo-1,6-dihydro-pyridazin-3-yl)-3-hydroxymethyl-pyridin-2-yl]-2*H*-phthalazin-1-one; and

6-*tert*-Butyl-8-fluoro-2-{3-hydroxymethyl-4-[1-methyl-5-(5-methyl-5-oxy-4,5,6,7-tetrahydro-pyrazolo[1,5-*a*]pyrazin-2-ylamino)-6-oxo-1,6-dihydro-pyridazin-3-yl]-pyridin-2-yl}-2*H*-phthalazin-1-one.

~~14. — A method for treating an inflammatory and/or autoimmune condition comprising administering to a patient in need thereof a therapeutically effective amount of the Btk inhibitor compound of any one of claims 1-13.~~

5

~~15. — A method for treating rheumatoid arthritis comprising administering to a patient in need thereof a therapeutically effective amount of the Btk inhibitor compound of any one of claims 1-13.~~

10

~~16. — A method for treating asthma comprising administering to a patient in need thereof a therapeutically effective amount of the Btk inhibitor compound of any one of claims 1-13.~~

~~17~~14. A pharmaceutical composition comprising the Btk inhibitor compound of any one of claims 1-13.

~~18~~15. A pharmaceutical composition comprising the Btk inhibitor compound of any one of
5 claims 1-13, admixed with at least one pharmaceutically acceptable carrier, excipient or diluent.

~~19~~16. ~~The use of a compound of any one of claims 1-13~~ for use as therapeutically active substance.

10 ~~20~~17. The compound of any one of claims 1-13 for use in treating an inflammatory and/or autoimmune condition.

~~21. The use of a compound of any one of claims 1-13 for treating an inflammatory and/or autoimmune condition.~~

15 ~~22~~18. The use of a compound of any one of claims 1-13 for the preparation of a medicament for treating an inflammatory and/or autoimmune condition.

19. The compound of any one of claims 1-13 for use in treating rheumatoid arthritis.

20 20. The use of a compound of any one of claims 1-13 for the preparation of a medicament for treating rheumatoid arthritis.

21. The compound of any one of claims 1-13 for use in treating asthma.

25 22. The use of a compound of any one of claims 1-13 for the preparation of a medicament for treating asthma.